tiprankstipranks

Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed

Crispr Therapeutics announced the hiring and appointment of Raju Prasad as CFO, effective March 14. He joins the company from William Blair & Company, where he served as a partner and senior equity research analyst covering cell therapy, gene therapy, and gene editing companies. Prasad succeeds Brendan Smith, who is leaving the company to pursue external opportunities.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CRSP:

Disclaimer & DisclosureReport an Issue